$2.93
2.33% yesterday
Nasdaq, Sep 27, 09:49 pm CET
ISIN
US1511901050
Symbol
CELU

Celularity Inc - Ordinary Shares - Class A Stock price

$2.99
-0.02 0.67% 1M
-1.95 39.47% 6M
+0.52 20.86% YTD
+0.66 28.16% 1Y
-71.31 95.98% 3Y
-96.51 97.00% 5Y
-95.01 96.95% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
-0.01 0.33%
ISIN
US1511901050
Symbol
CELU
Sector
Industry

Key metrics

Market capitalization $65.95m
Enterprise Value $131.14m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.76
P/S ratio (TTM) P/S ratio 2.90
P/B ratio (TTM) P/B ratio 1.42
Revenue growth (TTM) Revenue growth 26.68%
Revenue (TTM) Revenue $22.77m
EBIT (operating result TTM) EBIT $-76.48m
Free Cash Flow (TTM) Free Cash Flow $-39.73m
Cash position $230.00k
EPS (TTM) EPS $-11.33
Short interest 10.60%
Show more

Is Celularity Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Celularity Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Celularity Inc - Ordinary Shares - Class A:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Celularity Inc - Ordinary Shares - Class A:

Buy
100%

Financial data from Celularity Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '23
+/-
%
23 23
27% 27%
100%
- Direct Costs 25 25
13% 13%
111%
-2.57 -2.57
77% 77%
-11%
- Selling and Administrative Expenses 65 65
14% 14%
284%
- Research and Development Expense - -
-
-
-67 -67
52% 52%
-295%
- Depreciation and Amortization 9.31 9.31
1% 1%
41%
EBIT (Operating Income) EBIT -76 -76
48% 48%
-336%
Net Profit -196 -196
1,483% 1,483%
-862%

In millions USD.

Don't miss a Thing! We will send you all news about Celularity Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Celularity Inc - Ordinary Shares - Class A Stock News

Neutral
GlobeNewsWire
22 days ago
FLORHAM PARK, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, today announced that Robert J. Hariri, M.D., Ph.D., Chairman, CEO and founder, will present at H.C. Wainwright's 26th Annual Global Investment Conference being ...
Neutral
GlobeNewsWire
about one month ago
Seasoned Public Company Director and Finance Veteran Brings Extensive Track Record of Success in Facilitating the Growth of Shareholder Value Seasoned Public Company Director and Finance Veteran Brings Extensive Track Record of Success in Facilitating the Growth of Shareholder Value
Neutral
GlobeNewsWire
about one month ago
FLORHAM PARK, N.J., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Celularity Inc.  (Nasdaq: CELU) (the “Company”), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced that on August 22, 2024, the Company received notification from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) stati...
More Celularity Inc - Ordinary Shares - Class A News

Company Profile

Celularity, Inc. a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The firms CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. It is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. The company is headquartered in Florham Park, NJ.

Head office United States
CEO Robert Gordon
Employees 120
Founded 2016
Website www.celularity.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today